Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Summary

The present study is aiming at assessing the efficacy and safety of AVE5530 (25mg and 50mg) in a double-blind comparison with placebo in the management of patients with primary hypercholesterolemia. The main objective is to evaluate the effects of AVE5530 on LDL-C level reduction as adjunct to a controlled diet. The effects of AVE5530 on other lipid parameters will be assessed as secondary objectives.

Timeline

Start

2008-07

Primary completion

2008-11

Completion

2009-06

Drugs

Indications